Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction-Reference-Cited by-同舟云学术

Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction

Published:2023-02-24 Issue:1 Volume:41 Page:74-80
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Dias Maíse Moreira¹^ORCID,Mesquita Camelo Ricardo¹²^ORCID,de Magalhães Laura Peixoto¹^ORCID,Lemos Jardim Letícia¹²^ORCID,Gonçalves de Oliveira Andrea³^ORCID,Ribeiro Rosângela de Albuquerque⁴⁵^ORCID,Karla Brognoli Franco Vivian⁶^ORCID,Callado Fábia Michelle Rodrigues de Araújo⁷^ORCID,Lorenzato Cláudia Santos⁸^ORCID,Rezende Suely Meireles¹^ORCID,

Affiliation:

1. Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

2. Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the Netherlands

3. Fundação HEMOMINAS, Belo Horizonte, Brazil

4. Centro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza, Brazil

5. Hospital Universitário Walter Cantídeo, Universidade Federal do Ceará, Fortaleza, Brazil

6. Centro de Hematologia e Hemoterapia de Santa Catarina (HEMOSC), Florianópolis, Brazil

7. Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, Brazil

8. Hemocentro do Paraná (HEMEPAR), Curitiba, Brazil

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2023.2182853

Reference12 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Innovating immune tolerance induction for haemophilia

3. The importance of inhibitor eradication in clinically complicated hemophilia A patients

4. Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol